DSpace

DSpace at RU >    University Library >    Academic bibliography >

SFX Query

Files in This Item:

File Description SizeFormat
publisher's version146.18 kBAdobe PDFUnder Embargo

Title: Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors.
Author(s): Schattenberg, A.V.M.B. (104035919)
Meer, A. van der (194575209)
Preijers, F.W.M.B. (07401112X)
Schaap, N.P.M. (243161697)
Rinkes, M.J. (190743476)
Maazen, R.W.M. van der (110288629)
Allebes, W.A. (074327356)
Joosten, I. (075051877)
Witte, T.J.M. de (069336474)
Publication year: 2004
Document type: Article / Letter to editor
Journal: Bone Marrow Transplantation
ISSN: 0268-3369
Volume: vol. 33
Issue: iss. 11
Start page: p. 1115
End page: p. 1121
Abstract: We retrospectively analysed the outcome of voluntary unrelated donor (VUD)-SCT in 56 patients after conditioning without or with ATG. All received partially lymphocyte-depleted grafts. Four of 17 patients (24%) who were not given ATG rejected their grafts, as did one of 33 (3%) conditioned with ATG (P=0.02). The incidences of acute graft-versus-host disease grade III/IV were 29 and 6%, respectively (P=0.02), and probabilities of 1-year transplant-related mortality were 64% (95% CI, 44-84%) and 27% (95% CI, 12-42%), respectively (P=0.004). Projected at 3 years, probability of survival was 18% (95% CI, 2-34%) after conditioning without ATG and 60% (95% CI, 43-70%) after conditioning with ATG (P=0.002). Probabilities of disease-free survival (DFS) were 18% (95% CI, 2-34%) and 45% (95% CI, 27-63%), respectively (P=0.005). Patients who did not receive ATG had a probability of current DFS of 18% (95% CI, 3-34%) and this was 60% (95% CI, 43-77%) for the patients conditioned with ATG (P<0.001). We conclude that the addition of ATG to the conditioning regimen is associated with a significantly more favourable outcome in recipients of partially T-cell-depleted grafts from VUDs.
Subject: UMCN 1.2: Molecular diagnosis, prognosis and monitoring
UMCN 1.4: Immunotherapy, gene therapy and transplantation
UMCN 1.5: Interventional oncology
Organization: Haematology
Blood Transfusion and Transplantation Immunology
CHL
Radiation Oncology
Appears in Collections:Academic bibliography

Please use this identifier to cite or link to this item: http://hdl.handle.net/2066/57804

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

  DSpace Software Copyright © 2002-2011  Duraspace - Feedback